Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
September 26, 2006

Juvaris BioTherapeutics Gets SBIR Grant to Develop AML Vaccine Technology

  • Juvaris BioTherapeutics was awarded a one-year Phase I SBIR grant from the NCI in collaboration with David Claxton, M.D., at Penn State College of Medicine to develop a therapeutic vaccine approach for acute myelogenous leukemia (AML). Juvaris’ vaccine technology will be tested in rodent tumor models to evaluate its impact using an antigen-specific immunotherapeutic AML vaccine (JuvaVax).

    The SBIR grant application was supported by preclinical data generated by Juvaris and Dr. Claxton demonstrating significant protection in a rodent tumor model.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.